Quantifying the clinical impact of tissue reflex testing for liquid biopsy ESR1 mutation–negative cases with low ctDNA tumor fraction (TF) in HR(+)HER2(-) breast cancer.
Du J, Quintanilha J, Huang R, Heilmann A, Kahn A, Rozenblit M, Chiang A, Pusztai L, Krop I, Winer E, Graf R, Mills J, Gasco Hernandez A, Levy M, Lustberg M. Quantifying the clinical impact of tissue reflex testing for liquid biopsy ESR1 mutation–negative cases with low ctDNA tumor fraction (TF) in HR(+)HER2(-) breast cancer. Journal Of Clinical Oncology 2025, 43: 1065-1065. DOI: 10.1200/jco.2025.43.16_suppl.1065.Peer-Reviewed Original ResearchMetastatic breast cancerComprehensive genomic profilingPositive percent agreementClinicogenomic databaseTumor fractionCtDNA sheddingBC patientsReflex testBreast cancerFirst-line standard of careResistance to estrogen deprivationTissue comprehensive genomic profilingMetastatic breast cancer patientsFalse negative rateFoundationOne Liquid CDxFirst-line standardMutation-negative casesCohort of patientsStandard of careESR1 mutationsTumor genotypeEstrogen deprivationFirst-lineAromatase inhibitorsClinical impact
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply